Strong antiviral effect of the combination therapy (entecavir and tenofovir) in treatment experienced chronic HBV-mono infected patients with multidrug resistance or only partial…

Treatment of chronic HBV infected individuals with nucleos(t)ide analogs using sequential monotherapy has led to the selection of multiple resistant mutations, endangering patients with advanced liver disease. The aim of this cohort study was to investigate the efficacy and safety of tenofovir (245mg) and entecavir (1mg) in treatment experienced patients with multidrug resistant HBV or only partial responses to previous lines of therapy and advanced liver disease. Methods: Quantitative HBV-DNA measurement with a LLOD